中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2013年
4期
231-234
,共4页
裘力锋%赵岚%方燕飞%陈淑洁%姒健敏
裘力鋒%趙嵐%方燕飛%陳淑潔%姒健敏
구력봉%조람%방연비%진숙길%사건민
活组织检查%胃炎,萎缩性%二萜类%胃肠病用药%叶酸
活組織檢查%胃炎,萎縮性%二萜類%胃腸病用藥%葉痠
활조직검사%위염,위축성%이첩류%위장병용약%협산
Biopsy%Gastritis,atrophic%Diterpenes%Gastrointestinal agents%Folic acid
目的 应用定标活组织检查技术评价替普瑞酮联合叶酸治疗慢性萎缩性胃炎(CAG)的疗效.方法 选取H.pylori阴性的CAG患者224例,将其分为A组(96例,替普瑞酮50 mg/次,叶酸10 mg/次,每日3次)、B组(23例,替普瑞酮50 mg/次,每日3次)、C组(74例,非特异性治疗)、D组(31例,不治疗),疗程均为1年.观察治疗前后各组患者临床症状的改善情况.观察治疗前后各组患者定标活组织检查取材点的胃黏膜组织病理学改善情况.组间比较行卡方检验.结果 A、B、C、D组临床症状方面的总有效率分别为43.8％(42/96)、39.1％(9/23)、33.8％(25/74)、32.3％(10/31),组间比较差异无统计学意义(x2=2.328,P=0.507).在胃黏膜组织病理学显效率方面,A组和D组比较、A组和C组比较、B组和D组比较,差异均有统计学意义(x2=14.520、14.628、8.995,P均＜0.01).在胃黏膜组织病理学总有效率方面,A组和D组比较[49.8％(131/263)比24.2％(16/66)]、A组和C组比较[49.8％(131/263)比35.9％(66/184)]、B组和D组比较[44.7％(21/47)比24.2％(16/66)],差异均有统计学意义(x2=13.953、8.535、5.207,P均＜0.05).结论 单用替普瑞酮或替普瑞酮联合叶酸可显著改善CAG患者胃黏膜组织学病变.
目的 應用定標活組織檢查技術評價替普瑞酮聯閤葉痠治療慢性萎縮性胃炎(CAG)的療效.方法 選取H.pylori陰性的CAG患者224例,將其分為A組(96例,替普瑞酮50 mg/次,葉痠10 mg/次,每日3次)、B組(23例,替普瑞酮50 mg/次,每日3次)、C組(74例,非特異性治療)、D組(31例,不治療),療程均為1年.觀察治療前後各組患者臨床癥狀的改善情況.觀察治療前後各組患者定標活組織檢查取材點的胃黏膜組織病理學改善情況.組間比較行卡方檢驗.結果 A、B、C、D組臨床癥狀方麵的總有效率分彆為43.8％(42/96)、39.1％(9/23)、33.8％(25/74)、32.3％(10/31),組間比較差異無統計學意義(x2=2.328,P=0.507).在胃黏膜組織病理學顯效率方麵,A組和D組比較、A組和C組比較、B組和D組比較,差異均有統計學意義(x2=14.520、14.628、8.995,P均＜0.01).在胃黏膜組織病理學總有效率方麵,A組和D組比較[49.8％(131/263)比24.2％(16/66)]、A組和C組比較[49.8％(131/263)比35.9％(66/184)]、B組和D組比較[44.7％(21/47)比24.2％(16/66)],差異均有統計學意義(x2=13.953、8.535、5.207,P均＜0.05).結論 單用替普瑞酮或替普瑞酮聯閤葉痠可顯著改善CAG患者胃黏膜組織學病變.
목적 응용정표활조직검사기술평개체보서동연합협산치료만성위축성위염(CAG)적료효.방법 선취H.pylori음성적CAG환자224례,장기분위A조(96례,체보서동50 mg/차,협산10 mg/차,매일3차)、B조(23례,체보서동50 mg/차,매일3차)、C조(74례,비특이성치료)、D조(31례,불치료),료정균위1년.관찰치료전후각조환자림상증상적개선정황.관찰치료전후각조환자정표활조직검사취재점적위점막조직병이학개선정황.조간비교행잡방검험.결과 A、B、C、D조림상증상방면적총유효솔분별위43.8％(42/96)、39.1％(9/23)、33.8％(25/74)、32.3％(10/31),조간비교차이무통계학의의(x2=2.328,P=0.507).재위점막조직병이학현효솔방면,A조화D조비교、A조화C조비교、B조화D조비교,차이균유통계학의의(x2=14.520、14.628、8.995,P균＜0.01).재위점막조직병이학총유효솔방면,A조화D조비교[49.8％(131/263)비24.2％(16/66)]、A조화C조비교[49.8％(131/263)비35.9％(66/184)]、B조화D조비교[44.7％(21/47)비24.2％(16/66)],차이균유통계학의의(x2=13.953、8.535、5.207,P균＜0.05).결론 단용체보서동혹체보서동연합협산가현저개선CAG환자위점막조직학병변.
Objective To explore the efficacy of tepronone and folic acid in the treatment of chronic atrophic gastritis (CAG) evaluated by the marking targeting biopsy (MTB).Methods A total of 224 H.pylori negative CAG patients were selected and divided into group A (n 96,tepronone 50 mg/time,folic acid 10 mg/time,three times/day),group B (n=23,tepronone 50 mg/time,three times/day),group C (n=74,unspecific treatment) and group D (n=31,no treatment).The treatment course lasted for one year.The clinical symptoms improvement of each group was observed before and after treatment.The pathological improvement of gastric mucosa by MTB was inspected before and after treatment.The chi square test was performed for the comparison between groups.Results The total efficacy rates of group A,B,C and D were 43.8％ (42/96),39.1％ (9/23),33.8％(25/74) and 32.3％ (10/31) respectively,there was no significant difference between groups (x2 =2.328,P =0.507).For the significant efficacy rate of gastric mucosa pathological improvement,group A was compared with group D,group A was compared with group C and group B was comparedwith group D,the differences were significant (x2 =14.520,14.628 and 8.995,all P＜0.01).In the total efficacy rate of gastric mucosa pathological improvement,group A (49.8％,131/263) was compared with group D (24.2％,16/66),group A was compared with group C (35.9％,66/184)and group B (44.7％,21/47) was compared with group D,the differences were significant (x2 =13.953,8.535 and 5.207,all P＜0.05).Conclusion Teprenone alone or teprenone and folic acid combination can obviously improve pathological changes of CAG patients.
